Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6244 plus docetaxel versus docetaxel in second-line KRAS-mutant advanced NSCLC
2008-006323-31Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing AZD6244 + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
selumetinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006323-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006323-31.